Characterization of invasive Neisseria meningitidis isolates recovered from children in Turkey during a period of increased serogroup B disease, 2013–2017

Ceyhan, Mehmet; Özsürekçi, Yasemin; Lucidarme, Jay; Borrow, Ray

doi:10.1016/j.vaccine.2020.03.024

Cited by 7 publications

(7 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also detected high heterogeneity in NHBA peptides, but these prevalent NHBA peptides have been widely reported; an exception is NHBA peptide 1390, which is first described in this study. We observed a close association with types of NHBA peptides within ccs as well as those already described [36,41,51,57]. In our study, cc213 includes strains that also present NHBA peptide 115, which was not observed in Spain [36].…”

Section: Plos Onesupporting

confidence: 88%

“…In this study, we found 35 different fHbp peptides among all subfamilies/variants. Despite a high diversity, we have shown the prevalence of fHbp peptides 1, 24, 45, and 47 among the studied strains, which were predominantly associated with cc32, cc35, cc213, and cc461, respectively, as previously reported [36,40,41,51].…”

Section: Plos Onesupporting

confidence: 79%

“…Our data show that there is no prevalent circulation of a single MenB cc in Brazil, which has currently been observed for serogroup B IMD epidemiology in some European countries and not in North America [15,17,34]. cc213, cc35, and cc461 have previously been reported in Argentina, Australia, Colombia, Paraguay, Tunisia, Turkey, and Europe [23,22,[35][36][37][38][39][40][41]. Additionally, clonal diversity exhibiting a decline in cc41/44 and cc32 and an increase in cc269 and cc461 was observed in the Republic of Ireland over 19 years [39].…”

Section: Plos Onesupporting

confidence: 56%

See 2 more Smart Citations

Genomic surveillance of Neisseria meningitidis serogroup B invasive strains: Diversity of vaccine antigen types, Brazil, 2016-2018

et al. 2020

View full text Add to dashboard Cite

Background Neisseria meningitidis serogroup B remains a prominent cause of invasive meningococcal disease (IMD) in Brazil. Because two novel protein-based vaccines against serogroup B are available, the main purpose of this study was to provide data on the diversity and distribution of meningococcal vaccine antigen types circulating in Brazil. Methodology Genetic lineages, vaccine antigen types, and allele types of antimicrobial-associated resistance genes based on whole-genome sequencing of a collection of 145 Neisseria meningitidis serogroup B invasive strains recovered in Brazil from 2016 to 2018 were collected. Results A total of 11 clonal complexes (ccs) were identified among the 145 isolates, four of which were predominant, namely, cc461, cc35, cc32, and cc213, accounting for 72.0% of isolates. The most prevalent fHbp peptides were 24 (subfamily A/variant 2), 47 (subfamily A/variant 3), 1 (subfamily B/variant 1) and 45 (subfamily A/variant 3), which were predominantly associated with cc35, cc461, cc32, and cc213, respectively. The NadA peptide was detected in only 26.2% of the isolates. The most frequent NadA peptide 1 was found almost exclusively in cc32. We found seven NHBA peptides that accounted for 74.5% of isolates, and the newly described peptide 1390 was the most prevalent peptide exclusively associated with cc461. Mutated penA alleles were detected in 56.5% of the isolates, whereas no rpoB and gyrA mutant alleles were found. Conclusion During the study period, changes in the clonal structure of circulating strains were observed, without a predominance of a single hyperinvasive lineage, indicating that an epidemiologic shift has occurred that led to a diversity of vaccine antigen types in recent years in Brazil.

show abstract

Section: Plos Onesupporting

confidence: 88%

Section: Plos Onesupporting

confidence: 79%

Section: Plos Onesupporting

confidence: 56%

See 1 more Smart Citation

Genomic surveillance of Neisseria meningitidis serogroup B invasive strains: Diversity of vaccine antigen types, Brazil, 2016-2018

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Currently, two vaccines are developed and available for active immunization against the N. meningitidis B serogroup [16,17], but in Morocco the meningococcal B vaccine wasn't used yet and if this serogroup is identified, prevention will be limited to chemoprophylaxis. However, vaccination with tetravalent vaccine ACYW135 became mandatory for all Hajjis and visitors to Mecca.…”

Section: Co-resistance To Pg and Other Antibiotics (Table 4)mentioning

confidence: 99%

Epidemiology and antibiotic resistance profile of bacterial meningitis in Morocco from 2015 to 2018

Ikken

Charof

Benaouda³

et al. 2020

AMicr

View full text Add to dashboard Cite

Over a 4-year study period from 2015 to 2018, altogether 183 isolates of bacterial meningitis were collected from 12 hospitals covering the entire Moroccan territory. Neisseria meningitidis represented 58.5%, Streptococcus pneumoniae 35.5%, and Haemophilus influenzae type b 6%. H. influenzae type b mainly affected 5-year-olds and unvaccinated adults. N. meningitidis serogroup B represented 90.7% followed by serogroup W135 with 6.5%. Decreased susceptibility to penicillin G (DSPG) for all isolates accounted for 15.7%, with 11.6% being resistant to penicillin G (PG) and 4.1% decreased susceptibility. Cumulative results of all strains showed 2.7% decreased susceptibility to amoxicillin and 3.3% resistant, 2.2% of isolates were resistant to third-generation cephalosporin and 2.2% were decreased susceptible, 5.5% were resistant to chloramphenicol and 2.7% were resistant to rifampin. The frequency of DSPG observed in our study is more common in S. pneumoniae than in N. meningitidis (P < 0.05). These isolates have been found to be highly susceptible to antibiotics used for treatment and prophylaxis chemotherapy and the observed resistance remains rare. The impact of introduction of conjugate vaccines against H. influenzae type b and S. pneumoniae (PCVs) is an advantage in reducing meningitis cases due to these two species.

show abstract

“…There were more studies available on serogroup distribution from the EM region versus the NA region. Data were available from Iran (n = 2) [ 67 , 68 ], Kuwait (n = 1) [ 51 ], Qatar (n = 1) [ 69 ], Saudi Arabia (n = 6) [ 54 – 56 , 70 – 72 ], and Turkey (n = 8) [ 57 – 59 , 73 – 77 ], in the EM region (spanning 1987–2018), and from Egypt (n = 3) [ 61 , 78 , 79 ], Morocco (n = 6) [ 80 – 85 ], and Tunisia (n = 6) [ 64 , 86 – 90 ], in the NA region (spanning 1977–2019). Serogroups A, B and W were most frequently reported in the EM region, while B and C serogroups were most frequently reported in the NA region.…”

Section: Objective 2: Imd Epidemiologymentioning

confidence: 99%

Systematic review of invasive meningococcal disease epidemiology in the Eastern Mediterranean and North Africa region

Dogu

Oordt-Speets²,

Bruijn³

et al. 2021

BMC Infect Dis

Self Cite

View full text Add to dashboard Cite

Background Invasive meningococcal disease (IMD) represents a global health burden. However, its epidemiology in the Eastern Mediterranean (EM) and North Africa (NA) regions is currently not well understood. This review had four key objectives: to describe asymptomatic meningococcal carriage, IMD epidemiology (e.g. serogroup prevalence, case-fatality rates [CFRs]), IMD presentation and management (e.g. clinical diagnosis, antibiotic treatments) and economic impact and evaluation (including health technology assessment [HTA] recommendations) in EM and NA. Methods A systematic literature search (MEDLINE and EMBASE) was conducted (January 2000 to February 2021). Search strings included meningococcal disease and the regions/countries of interest. Identified publications were screened sequentially by title/abstract, followed by screening of the full-text article; articles were also assessed on methodological quality. Literature reviews, genetic sequencing or diagnostic accuracy studies, or other non-pertinent publication type were excluded. An additional grey literature search (non-peer-reviewed sources; start date January 2000) was conducted to the end of April 2019. Results Of the 1745 publications identified, 79 were eligible for the final analysis (n = 61 for EM and n = 19 for NA; one study was relevant to both). Asymptomatic meningococcal carriage rates were 0–33% in risk groups (e.g. military personnel, pilgrims) in EM (no data in NA). In terms of epidemiology, serogroups A, B and W were most prevalent in EM compared with serogroups B and C in NA. IMD incidence was 0–20.5/100,000 in EM and 0.1–3.75/100,000 in NA (reported by 7/15 countries in EM and 3/5 countries in NA). CFRs were heterogenous across the EM, ranging from 0 to 57.9%, but were generally lower than 50%. Limited NA data showed a CFR of 0–50%. Data were also limited in terms of IMD presentation and management, particularly relating to clinical diagnosis/antibiotic treatment. No economic evaluation or HTA studies were found. Conclusions High-risk groups remain a significant reservoir of asymptomatic meningococcal carriage. It is probable that inadequacies in national surveillance systems have contributed to the gaps identified. There is consequently a pressing need to improve national surveillance systems in order to estimate the true burden of IMD and guide appropriate prevention and control programmes in these regions.

show abstract

Characterization of invasive Neisseria meningitidis isolates recovered from children in Turkey during a period of increased serogroup B disease, 2013–2017

Cited by 7 publications

References 40 publications

Genomic surveillance of Neisseria meningitidis serogroup B invasive strains: Diversity of vaccine antigen types, Brazil, 2016-2018

Genomic surveillance of Neisseria meningitidis serogroup B invasive strains: Diversity of vaccine antigen types, Brazil, 2016-2018

Epidemiology and antibiotic resistance profile of bacterial meningitis in Morocco from 2015 to 2018

Systematic review of invasive meningococcal disease epidemiology in the Eastern Mediterranean and North Africa region

Contact Info

Product

Resources

About